Type "is GHK-Cu legal" into a search bar and you'll get banned, approved and back on, sometimes in one thread. Going into 2026, FDA tracked GHK-Cu as two separate entries on its compounding lists, and both moved this year. Everyone wants a one-word answer. There isn't one.
GHK-Cu's FDA status is about pharmacy compounding, not approval
FDA has never approved GHK-Cu as a drug. The 2026 news was about something narrower: which raw ingredients pharmacies may use for compounding, meaning making a custom drug for one patient's prescription. While FDA reviews a nominated ingredient, it files it in a bucket. Category 1 means under evaluation. Category 2 means FDA flagged a significant safety risk. Neither bucket is an approval.
The proof: two entries, one withdrawal, one do-over
Here's what's actually going on.
September 2023: the first entry went into Category 2. On September 29, 2023, FDA placed one of its two GHK-Cu entries in Category 2. Its stated worry was possible immune reactions from clumping and impurities, with "limited data in humans" (FDA, archived January 2025). It was one of more than a dozen peptides moved that month (FDA Law Blog, 2026).
April 2026: the nomination was withdrawn, so the entry came off. On April 15, FDA gave seven days' notice that 12 peptides would leave Category 2 because their nominations had been withdrawn (Orrick, 2026). They came off on April 22, and FDA's page now lists that GHK-Cu entry under "nominated but withdrawn" (FDA).
Then the do-over. The second entry sat in Category 1, and it was pulled on April 22 too, for the same reason. On May 5, one nominator clarified it had meant to withdraw only its nomination for the other entry and wanted to keep this one. FDA said it would add the entry back, and its May 14 list shows it in Category 1 (FDA 503A categories).
Why removal isn't approval. Leaving Category 2 "lifted a safety designation but did not make any peptide eligible for compounding," as Holland & Knight put it (Holland & Knight, October 2026). And Drugs@FDA, FDA's database of approved drugs, lists no GHK-Cu product.
What's next: an advisory meeting with no date. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027 (FDA 503A categories), alongside four other peptides. No date is set yet (Holland & Knight). Committee votes are advice. Changing the official list still takes rulemaking (FDA Law Blog).
"But it's in cosmetics." Yes, under another name, copper tripeptide-1 (PubChem). Whether a product counts as a cosmetic or a drug depends on its intended use, and cosmetic ingredients, other than color additives, don't need FDA approval before sale (FDA). Different product, different rulebook.
The big learning lesson
Keep reading: The FDA "peptide ban" of 2026: what actually happened · What is GHK-Cu? The copper peptide, explained · How to read a peptide certificate of analysis
Frequently asked questions
Is GHK-Cu FDA approved?
No. FDA has never approved GHK-Cu as a drug, and Drugs@FDA lists no GHK-Cu product.
Is GHK-Cu still on FDA's Category 2 list?
No. The GHK-Cu entry FDA put in Category 2 in September 2023 came off on April 22, 2026, after its nomination was withdrawn. The other GHK-Cu entry sits in Category 1, under evaluation.
What happens next for GHK-Cu at the FDA?
FDA has said it intends to consult its advisory committee before the end of February 2027, and no date is set yet. A vote there is advice, and changing the official list still takes rulemaking.